Minimal Residual Disease Testing Market Size to Reach USD 7.97 Billion by 2035 at 11.50% CAGR | Industry Report by SNS Insider

The U.S. minimal residual disease (MRD) testing market is projected to reach $2.37B by 2035, with Europe expected to reach $1.98B. Growth is attributed to FDA-cleared MRD assays, next-generation sequencing (NGS), liquid biopsy adoption, and increased uptake of precision oncology.

Analysis

The real signal here is not the size of the addressable market; it is that MRD is moving from a research tool to a recurring reimbursement-backed workflow. That favors companies with proprietary longitudinal datasets and clinical evidence density — especially NTRA, and secondarily GH/PSNL — because payer adoption tends to create winner-take-most economics around the assay with the deepest outcome data. Smaller entrants without durable reimbursement coverage face a classic commercialization trap: high TAM, but weak pricing power and repeated validation costs.

The second-order benefit sits further upstream in sequencing utilization: ILMN and reagent-heavy tool suppliers gain pull-through if MRD volumes rise, but their upside is slower and lower quality because application-layer vendors capture most of the value creation. In Europe, the path is likely longer and more fragmented than the U.S., so any revenue inflection should be U.S.-led over the next 2-4 quarters, with Europe more of a 12-24 month option on payer normalization. That means headline TAM expansion is more relevant for multiples than for near-term estimates.

Consensus may be overestimating how quickly this converts into P&L. The reversal risk is not scientific failure; it is reimbursement friction, payer step-edits, or evidence standards that force narrower test frequency, which would cap utilization growth even if adoption continues. The thesis would be falsified if quarterly MRD volume growth decelerates materially, ASPs compress, or CMS/private payer coverage stalls.

Key Decisions for Investors

• Long NTRA on pullbacks; 6-12 month thesis is continued share gains in validated MRD surveillance. Fails if MRD volume growth slows or reimbursement expands less than expected.
• Pair trade: long NTRA / short GH or PSNL for a 3-6 month relative-value expression of platform consolidation. Target 10-15% relative outperformance if reimbursement and guideline adoption continue.
• Use ILMN as a lower-beta picks-and-shovels watchlist name, not a chase buy; only add on evidence of sequencing consumables acceleration over the next 1-2 quarters.
• Set a hard alert on payer coverage and management commentary around repeat-test frequency. If private payers tighten coverage, trim longs and expect a fast multiple reset.